Pfizer China And Hangzhou Sciwind Biosciences Sign Strategic Cooperation On Ecnoglutide Injection

In a significant development for China’s healthcare industry, Hangzhou Sciwind Biosciences and Pfizer China have announced a strategic cooperation agreement focused on the commercialization of Ecnoglutide injection, a next-generation therapeutic.  

Ecnoglutide, developed by Sciwind, is designed to address metabolic and chronic conditions with improved efficacy and patient convenience. By partnering with Pfizer, Sciwind gains access to Pfizer’s extensive commercial network, regulatory expertise, and global market experience.  

The collaboration is expected to enhance patient access to advanced therapies, accelerate innovation in metabolic disease treatment, and reinforce China’s position in the global biopharma landscape. Industry experts view this agreement as a milestone that combines local R&D strength with international commercialization capabilities.  

Key Highlights  

• Pfizer China and Sciwind Biosciences sign strategic cooperation agreement  
• Focus on commercialization of next-generation Ecnoglutide injection  
• Partnership enhances patient access and market expansion  
• Combines local innovation with Pfizer’s global expertise  
• Strengthens China’s biopharmaceutical ecosystem  

Sources: Reuters, Business Standard, Economic Times